Folgen

  • Ozempic and Cancer Risk — Uncover what the science really says with Dr. Ben Synth

    Ozempic and Cancer Risk — Uncover what the science really says with Dr. Ben Synth
    Apr 7 2026
    Join Dr. Ben Synth as he cuts through the noise surrounding Ozempic and cancer risk, revealing why the truth is far more fascinating than fear-mongering headlines. From thyroid cancer warnings to research suggesting these drugs might actually prevent cancer, you'll learn to navigate contradictory medical evidence with clarity.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Mehr anzeigen Weniger anzeigen
    1 Min.
  • Ozempic and Cancer Risk — Reading Between the Headlines

    Ozempic and Cancer Risk — Reading Between the Headlines
    Apr 7 2026
    Ben Synth explores the conflicting evidence on GLP-1 drugs and cancer risk, analyzing why a French study showed increased thyroid cancer risk while a 2.5-million-patient international study found none. He examines detection bias, study design, and emerging protective effects against other cancers.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Mehr anzeigen Weniger anzeigen
    28 Min.
  • Ozempic and Cancer Risk — What We Know - The Plot Twist

    Ozempic and Cancer Risk — What We Know - The Plot Twist
    Apr 7 2026
    Host Ben Synth explores how GLP-1 drugs like Ozempic, which carry thyroid cancer warnings from rodent studies, are showing unexpected cancer-protective effects in humans. New research reveals colon cancer patients on these medications have half the mortality rate, while studies show reduced risk across twelve obesity-related cancers—challenging assumptions about these widely-prescribed medications.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Mehr anzeigen Weniger anzeigen
    26 Min.
  • Ozempic and Cancer Risk — What We Know - The Black Box That Started It All

    Ozempic and Cancer Risk — What We Know - The Black Box That Started It All
    Apr 7 2026
    AI host Ben Synth explores the FDA's thyroid cancer warning on GLP-1 drugs like Ozempic, revealing it stems from rodent studies, not human data. Ben examines massive multinational studies showing no substantial cancer risk increase, discusses detection bias explaining apparent associations, and highlights emerging research suggesting these medications may actually protect against certain cancers.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Mehr anzeigen Weniger anzeigen
    23 Min.